| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Pinelopi Manousou | Q88955142 |
| Roberta Forlano | Q90967036 | ||
| Benjamin Mullish | Q42838708 | ||
| P2093 | author name string | Rooshi Nathwani | |
| Ameet Dhar | |||
| David Kockerling | |||
| P2860 | cites work | Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis | Q24185895 |
| Guidelines on the management of ascites in cirrhosis | Q24676541 | ||
| Human albumin in the management of complications of liver cirrhosis | Q26852608 | ||
| Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis | Q27013775 | ||
| Rifaximin treatment in hepatic encephalopathy | Q28277660 | ||
| Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis | Q30234533 | ||
| Anticoagulation in cirrhosis: a new paradigm? | Q30235307 | ||
| The burden of liver disease in Europe: a review of available epidemiological data | Q30590517 | ||
| Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multic | Q31043168 | ||
| Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials | Q33200604 | ||
| The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club | Q33966809 | ||
| Management of cirrhosis and ascites | Q33977520 | ||
| Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials | Q34077523 | ||
| Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial | Q34255207 | ||
| Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study | Q34276429 | ||
| Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. | Q34469981 | ||
| Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials | Q34487499 | ||
| Can Non-Selective Beta-Blockers (NSBBs) Prevent Enlargement of Small Esophageal Varices in Patients with Cirrhosis? A Meta-analysis | Q47194571 | ||
| Statins in cirrhosis-Ready for prime time | Q48097930 | ||
| Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. | Q48105576 | ||
| Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. | Q48122792 | ||
| Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. | Q48182745 | ||
| Prevention of progression from small to large varices: are we there yet? An updated meta-analysis | Q48326607 | ||
| Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. | Q48462438 | ||
| A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy | Q48655913 | ||
| Coffee Consumption and Prevention of Cirrhosis - In Support of the Caffeine Hypothesis | Q50148162 | ||
| Beta-blockers in patients with advanced cirrhosis: Red light, green light, yellow light…. | Q50202878 | ||
| Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension? | Q50255140 | ||
| Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. | Q50709932 | ||
| Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. | Q50885984 | ||
| l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. | Q51344453 | ||
| Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. | Q51397672 | ||
| Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. | Q51792687 | ||
| Proton Pump Inhibitor Administration Triggers Encephalopathy in Cirrhotic Patients by Modulating Blood-Brain Barrier Drug Transport. | Q52096132 | ||
| Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. | Q52909369 | ||
| Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. | Q53081546 | ||
| Dose-dependency of clonidine's effects in ascitic cirrhotic rats: comparison with α1-adrenergic agonist midodrine. | Q53449356 | ||
| Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites. | Q53686281 | ||
| EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. | Q55497819 | ||
| Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial | Q56379261 | ||
| L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis | Q56456331 | ||
| Coffee and tea breaks for liver health | Q56958980 | ||
| Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol | Q57168135 | ||
| Expanding consensus in portal hypertension | Q58034372 | ||
| Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial | Q34529788 | ||
| Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy | Q34576485 | ||
| Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. | Q34600223 | ||
| Statin use in patients with cirrhosis: a retrospective cohort study | Q34661975 | ||
| Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo | Q34985317 | ||
| The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis | Q35170336 | ||
| The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials | Q35657152 | ||
| Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis | Q35859138 | ||
| Carvedilol Improves Inflammatory Response, Oxidative Stress and Fibrosis in the Alcohol-Induced Liver Injury in Rats by Regulating Kuppfer Cells and Hepatic Stellate Cells | Q35927446 | ||
| Improving survival in decompensated cirrhosis | Q36090423 | ||
| Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis | Q36393781 | ||
| Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. | Q36505496 | ||
| Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis | Q36802060 | ||
| Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. | Q37019499 | ||
| A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome | Q37061659 | ||
| Evaluation and management of patients with refractory ascites | Q37122130 | ||
| Proton pump inhibitors in cirrhosis: tradition or evidence based practice? | Q37169345 | ||
| Rifaximin in the treatment of hepatic encephalopathy | Q37355818 | ||
| Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. | Q37440725 | ||
| An updated dose-response meta-analysis of coffee consumption and liver cancer risk | Q37464692 | ||
| Molecular Bases Underlying the Hepatoprotective Effects of Coffee. | Q37628490 | ||
| EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis | Q37773059 | ||
| Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis | Q37874694 | ||
| Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. | Q37983998 | ||
| Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis | Q38051955 | ||
| Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications | Q38083035 | ||
| Human serum albumin, systemic inflammation, and cirrhosis. | Q38206059 | ||
| Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis | Q38272635 | ||
| Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials | Q38315552 | ||
| Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis | Q38319073 | ||
| Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects | Q38656007 | ||
| Beta-blockers in patients with advanced liver disease: Has the dust settled? | Q38673738 | ||
| The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. | Q38676257 | ||
| Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis | Q38706114 | ||
| Fecal Microbiota Transplant from a Rational Stool Donor Improves Hepatic Encephalopathy: A Randomized Clinical Trial | Q38740977 | ||
| Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis | Q58034394 | ||
| Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices | Q58102151 | ||
| Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast | Q58833167 | ||
| The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines | Q60174336 | ||
| Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation | Q61796520 | ||
| Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. | Q64970387 | ||
| Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis | Q71756341 | ||
| Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites | Q73308039 | ||
| Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system | Q79152275 | ||
| Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial | Q80720162 | ||
| The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease | Q83207473 | ||
| Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites | Q83574872 | ||
| Management of adult patients with ascites due to cirrhosis: an update | Q83932911 | ||
| Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose | Q84164852 | ||
| Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy | Q84403028 | ||
| Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study | Q84546778 | ||
| Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity | Q84749771 | ||
| The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis | Q84762999 | ||
| Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis | Q85631083 | ||
| α1 and α2-adrenergic agonists on cirrhotic patients with refractory ascites | Q85924133 | ||
| Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study | Q86152266 | ||
| Liver cirrhosis | Q87200165 | ||
| Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver | Q87416507 | ||
| Proton Pump Inhibitors and the Possible Development of Hepatic Encephalopathy in Cirrhotic Patients: True Association or Residual Confounding? | Q88009336 | ||
| The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis | Q88153292 | ||
| EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis | Q88353946 | ||
| Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases | Q88636602 | ||
| Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis | Q88869445 | ||
| Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters | Q89252223 | ||
| Diagnosis and treatment of ascites | Q89894406 | ||
| Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study | Q38746130 | ||
| Anticoagulation in chronic liver disease | Q38770377 | ||
| Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention. | Q38806797 | ||
| Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide | Q38869934 | ||
| Treatment of Patients with Cirrhosis | Q38936166 | ||
| Beta blockers and cirrhosis, 2016. | Q38975429 | ||
| Beta adrenergic blockade and decompensated cirrhosis. | Q39013562 | ||
| Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study | Q39378097 | ||
| Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. | Q39542998 | ||
| The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis. | Q39688617 | ||
| Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers | Q39908375 | ||
| Lactulose | Q39997360 | ||
| Management of ascites and hepatorenal syndrome. | Q40081708 | ||
| Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis | Q40100867 | ||
| Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. | Q40282684 | ||
| Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. | Q40285529 | ||
| Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure | Q40372534 | ||
| Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis | Q40379898 | ||
| Loop diuretic therapy in liver cirrhosis with ascites | Q40385335 | ||
| Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis | Q41591557 | ||
| Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study | Q41613676 | ||
| Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review | Q41698366 | ||
| Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? | Q42267541 | ||
| Rifaximin therapy and hepatic encephalopathy: Pros and cons | Q42324150 | ||
| Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. | Q42634652 | ||
| Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites | Q43003630 | ||
| Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis | Q43281073 | ||
| Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage | Q43560935 | ||
| Coffee, caffeine, and the risk of liver cirrhosis | Q43737586 | ||
| The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis | Q44239223 | ||
| The complications of diuretic therapy in patients with cirrhosis | Q44322569 | ||
| Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. | Q44439466 | ||
| Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. | Q44779682 | ||
| Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity | Q44887140 | ||
| A randomized controlled trial of acarbose in hepatic encephalopathy | Q45259881 | ||
| beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. | Q45976511 | ||
| Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial | Q46126097 | ||
| Is acarbose an effective drug for treating patients with cirrhosis and hepatic encephalopathy? | Q46787163 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cirrhosis | Q147778 |
| cirrosis | Q12569389 | ||
| gastroenterology | Q120569 | ||
| rifaximin | Q416073 | ||
| gastrointestinal bleeding | Q1495657 | ||
| esophageal and gastric varices | Q54911777 | ||
| P304 | page(s) | 888-908 | |
| P577 | publication date | 2019-02-01 | |
| 2019-02-28 | |||
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Current and future pharmacological therapies for managing cirrhosis and its complications | |
| P478 | volume | 25 |
| Q91867520 | Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology |
| Q99239921 | Laparoscopic splenectomy via the spleen bed in combination with selective esophagogastric devascularization for patients with cirrhotic portal hypertension: a single-institution experience |
| Q64940894 | Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis. |
Search more.